ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

I now turn the call over to Justin Shakma, Chief Business Officer. Please proceed. Good morning, and thank you for joining our first quarter 2025 earnings conference call. This morning, we issued a press release detailing our financial results and commercial highlights, which is available in the investor and media section of our website at ars-pharma.com. With me on the call are Richard Lowenthal, our co-founder, president, and CEO, who will review recent corporate updates and achievements. Eric Peraz, our chief commercial officer, who will cover our commercial activities and progress. And Kathy Scott, our CFO, who will provide a summary of our financial results and cash position. Before we begin, please note that today's remarks may contain forward-looking statements. Actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Rich. Thank you, Justin. Good morning, and thank you all for joining us on this call. We're off to a strong start in 2025 as we continue to execute the nationwide launch of NEFI, the first and only needle-free epinephrine treatment approved for type 1 allergic reactions, including anaphylaxis. We believe NEFI has blockbuster potential, addressing a U.S. market potential of 3 billion net sales in the near term, comprised of about 6.5 million patients who have been prescribed epinephrine over the past three years. Beyond this, an additional 13.5 million diagnosed patients have no epinephrine prescription, and many struggle with needle anxiety and portability concerns. Only 3.2 million patients actually fill their epinephrine autoinjector prescriptions underscoring the substantial unmet medical need that NEFI is uniquely positioned to solve. With only ...